Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
News and updates for Alterity Therapeutics Limited (ATHE) center on its progress as a clinical stage biotechnology company developing disease modifying treatments for neurodegenerative diseases. The company’s announcements emphasize its initial focus on Parkinson’s disease and related disorders, particularly Multiple System Atrophy (MSA), and the development of its lead oral agent ATH434.
Investors and followers of ATHE can expect regular news about clinical trial milestones and data presentations. Alterity has reported positive results from its ATH434‑201 randomized, double‑blind, placebo‑controlled Phase 2 trial in MSA, as well as topline data from the ATH434‑202 open‑label Phase 2 trial in more advanced MSA. Company news often highlights analyses of UMSARS Part I activities of daily living scores, orthostatic hypotension symptom assessments, wearable sensor data, and neuroimaging and biomarker endpoints such as brain iron and the MSA Atrophy Index.
Alterity’s news flow also includes regulatory and designation updates, such as Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the FDA and European Commission for ATH434 in MSA. Additional items cover participation in major neurology and movement disorder conferences, where the company presents new analyses, biomarker findings, and natural history study results, as well as appearances at healthcare and biotech investor events.
On this page, readers can follow announcements about capital raises, quarterly cash flow reports, and corporate presentations that describe Alterity’s cash position, development plans, and engagement with regulators. For those tracking ATHE, the news stream provides context on how the company is advancing ATH434 in MSA, refining its biomarker strategy, and interacting with the scientific and investment communities over time.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced the opening of enrollment for its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) in the UK. This trial aims to assess the treatment's impact on neuroimaging and protein biomarkers, targeting around 60 adult patients. ATH434 has shown promise in preclinical studies, demonstrating the ability to inhibit pathogenic protein aggregation and restore normal iron balance in the brain. MSA affects approximately 15,000 individuals in the U.S., with no current market-approved drugs to slow its progression.
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has commenced its Phase 2 clinical trial for ATH434 in New Zealand, focusing on Multiple System Atrophy (MSA), a rare Parkinsonian disorder. The regulatory bodies in the U.K. and Italy have granted approval for this trial. The company reported a cash balance of A$34.8 million as of June 30, 2022, with cash outflows of A$4.4 million. Additionally, it received A$4.1 million from the R&D Tax Incentive Scheme, supporting its research and development efforts.
Alterity Therapeutics has announced the dosing of the first patient in its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA), a severe neurodegenerative disease. This trial, which aims to enroll approximately 60 adult patients, is designed to evaluate the safety and efficacy of ATH434 over 12 months. MSA affects about 15,000 individuals in the U.S., and current treatments fail to slow its progression. ATH434 has shown promise in preclinical studies and is the first small molecule designed to target the pathological proteins involved in MSA.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received authorization from the Italian Medicines Agency to conduct a Phase 2 clinical trial for ATH434 targeting Multiple System Atrophy (MSA), a severe Parkinsonian disorder. The trial aims to enroll approximately 60 patients, assessing ATH434's impact on biomarkers and clinical endpoints over 12 months. This approval affirms the company’s strategy to reach a global patient base affected by MSA, with ongoing efforts to open study sites in New Zealand, the UK, and Italy. ATH434, previously successful in Phase 1 trials, has Orphan designation for MSA treatment.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that its Phase 2 clinical trial for ATH434, aimed at treating Multiple System Atrophy (MSA), is now open for enrollment in New Zealand. MSA is a rare neurodegenerative disease characterized by rapid progression and severe disability. ATH434 is intended to reduce α-synuclein accumulation and restore iron balance in the brain, addressing the disease's underlying pathology. The trial will include approximately 60 patients, assessing efficacy and safety over a 12-month treatment period.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received approval from the UK's Medicines & Healthcare products Regulatory Agency (MHRA) for its Phase 2 clinical trial of ATH434, aimed at treating Multiple System Atrophy (MSA), a debilitating neurodegenerative condition. The trial will begin in New Zealand and expand to other regions, including the UK and the U.S. ATH434 targets protein aggregation and aims to improve patient outcomes. This follows a successful Phase 1 trial, highlighting ATH434's potential as a novel treatment for patients with no current options.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced new data from its ongoing bioMUSE study at the AAN Annual Meeting on April 6, 2022. This natural history study tracks disease progression in early Multiple System Atrophy (MSA) patients. It highlights a correlation between iron accumulation in the brain and disease severity, reinforcing the potential of quantitative susceptibility mapping as a biomarker. The study included data from 52 individuals and supports the upcoming global Phase 2 trial of ATH434, aimed at treating MSA by reducing iron accumulation and inhibiting protein aggregation.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on treatments for neurodegenerative diseases, announced that CEO David Stamler will present at the 34th Annual Roth Conference on March 14-15, 2022, in Dana Point, California. The company's lead asset, ATH434, targets Parkinsonian disorders, while its drug discovery platform aims to develop innovative treatments. A recorded presentation is available on the Alterity website.
Alterity Therapeutics (ATHE) has announced the publication of research demonstrating that its drug candidate, ATH434, shows promise in treating Multiple System Atrophy (MSA). Published in the Journal of Parkinson's Disease, the study revealed that ATH434 reduced toxic forms of α-synuclein in a murine model, preserved neurons, and improved motor performance. The research led by Dr. David Finkelstein highlighted ATH434's potential for clinical application, with ongoing Phase 2 trials planned. The compound has received Orphan Drug designation from the FDA and the European Commission.
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has received authorization from New Zealand's Medsafe for a Phase 2 clinical trial of its lead drug candidate ATH434, targeting Multiple System Atrophy (MSA). The trial aims to assess ATH434's impact on imaging and biomarkers over 12 months. The company reported a cash position of A$37M as of December 31, 2021, with operating cash outflows of A$4M. Additionally, a recent US patent grants exclusivity for a new class of iron chaperones, potentially beneficial for treating Parkinson's and Alzheimer's diseases.